Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 24310 - Ph1/1b single agent in combo with an androgen receptor in patients with prostate
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer
Disease Types: Prostate
Available at: Arlington Heights, Chicago, Niles